Table 2 Genotype frequencies.

From: Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

 

No. of patients (%)

eNOS + 894

 GT

84 (54%)

 GG

60 (38%)

 TT

13 (8%)

 Unknown

12

eNOS VNTR

 4bb

121 (74%)

 4ab

34 (21%)

 4aa

9 (5%)

 Unknown

5

VEGF + 936

 CC

121 (72%)

 CT

43 (26%)

 TT

3 (2%)

 Unknown

2

Back to article page